Olverembatinib Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Olverembatinib Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 23 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Olverembatinib can convert its Small molecule drug profile and Bcr-Abl T315I x c-Kit biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Olverembatinib (query alias: Olverembatinib) |
|---|---|
| Modality / target | Small molecule drug; Bcr-Abl T315I x c-Kit; Bcr-Abl T315I inhibitors, c-Kit inhibitors |
| Highest global status | Approved |
| Originator | Guangzhou Shunjian Biomedical Technology Co. Ltd. |
| Active developers | Ascentage Pharma Group, Inc., Guangzhou Shunjian Biomedical Technology Co. Ltd., Ascentage Pharma Group International Co., Ltd. |
The MCP disease footprint includes Aggressive-Phase Chronic Myelocytic Leukemia, Chronic phase chronic myeloid leukemia, SDH-deficient Gastrointestinal Stromal Tumors. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| ChiCTR2600126815 | Phase 4 | Recruiting | 79 | Progression-Free Survival (PFS) |
| ChiCTR2600124345 | Early Phase 1 | Not yet recruiting | 35 | PFS, Progression Free Survival |
| NCT07493161 | Not Applicable | Recruiting | 110 | Rate of BCR::ABL1 ≤0.01% at 90 days (after three cycles of treatment) |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
Olverembatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: Meta-analysis of efficacy and safety outcomes.
Not Applicable; n=253; evaluation: Positive. Reported fields: CMR(at 3 months) = 84.0 % ( 67.0 - 96.0)
A phase 3 study of olverembatinib (HQP1351) in patients with chronic-phase chronic myeloid leukemia: POLARIS-2 trial in progress.
Phase 3; n=270; evaluation: Positive. Reported fields: -; MMR(24-week) = 39.0 %
Olverembatinib (HQP1351) combined with blinatumomab in patients with lymphoid blast phase chronic myeloid leukemia (CML-LBP) or Philadelphia chromosome–positive B-cell precursor acute lymphoblastic leukemia (Ph<sup>+ </sup>BCP-ALL).
Phase 1; n=9; evaluation: Positive. Reported fields: AE(grade 3) = Four patients experienced grade 3 AEs related to olverembatinib, including increased lipase, neutropenia, thrombocytopenia, and pancreatitis.
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Olverembatinib addresses Aggressive-Phase Chronic Myelocytic Leukemia, Chronic phase chronic myeloid leukemia, SDH-deficient Gastrointestinal Stromal Tumors. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 4 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2024-06-14 | 亚盛医药集团与Takeda International订立独家选择权协议 | Approved | US$100.0M upfront; US$1,200.0M milestones |
| 2021-07-14 | Ascentage Pharma and Innovent Biologics Reach Multifaceted Strategic Agreement Totaling US$245 Million Including Commercialization of Olverembatinib (HQP1351) in China, Joint Clinical Development of Lisaftoclax (APG-2575) and Equity Investment | Phase 3 | US$30.0M upfront; US$115.0M milestones; US$145.0M stated total |
| 2019-01-06 | MD Anderson Cancer Center and Ascentage Pharma announce strategic alliance in cancer drug development | Phase 1 | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Therapeutic index across KRAS/BRAF mutation subgroups
- On-target toxicity and adaptive MAPK resistance
- Lack of matched efficacy results in the current MCP result set
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 23 July 2026. Counts and status fields may change as source records update.
